Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Memantine: Marketed in EU to treat Alzheimer's disease (AD)

Preliminary data from a double-blind trial showed that Memantine plus acetylcholinesterase inhibitors failed to significantly improve

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE